Drug shortages delay cancer clinical trials.
Merrill
M
Goozner
D000227:Adenine Nucleotides / Q000600:supply & distribution; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000600:supply & distribution*; D001087:Arabinonucleosides / Q000600:supply & distribution; D002648:Child; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards; D000077866:Clofarabine; D003561:Cytarabine / Q000600:supply & distribution; D003630:Daunorubicin / Q000600:supply & distribution; D017277:Drug Approval; D004345:Drug Industry / Q000592:standards / Q000639:trends*; D016568:Drugs, Generic / Q000008:administration & dosage / Q000600:supply & distribution*; D005060:Europe; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D054547:National Cancer Institute (U.S.); D018579:Patient Selection; D016019:Survival Analysis; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D000227:Adenine Nucleotides; D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D016568:Drugs, Generic; D003561:Cytarabine; D000077866:Clofarabine; D003630:Daunorubicin